LLLucia Lebrato-Hernández

Lucia Lebrato-Hernández

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucia Lebrato-Hernández has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antithrombotic Treatment after Carotid Stenting in Patients with Concomitant Atrial Fibrillation

    by B. Pardo-Galiana, M. Medina-Rodriguez, M. Millan-Vazquez, J.A. Cabezas-Rodriguez, L. Lebrato-Hernandez, L. Ainz-Gomez, E. Zapata-Arriaza, J. Ortega, A. de Albóniga-Chindurza, J. Montaner, et al.

    Single-cell RNA sequencing (scRNA-seq) quantifies gene expression for individual cells in a sample, which allows distinct cell-type populations to be identified and characterized. An important step in many scRNA-seq analysis pipelines is the annotation of cells into known cell-types. While this can be achieved using experimental techniques, such as fluorescence-activated cell sorting, these approaches are impractical for large numbers of cells. This motivates the development of data-driven cell-type annotation methods. We find limitations with current approaches due to the reliance on known marker genes or from overfitting because of systematic differences between studies or batch effects. Here, we present a statistical approach that leverages public datasets to combine information across thousands of genes, uses a latent variable model to define cell-type-specific barcodes and account for batch effect variation, and probabilistically annotates cell-type identity. The barcoding approach also provides a new way to discover marker genes. Using a range of datasets, including those generated to represent imperfect real-world reference data, we demonstrate that our approach substantially outperforms current reference-based methods, in particular when predicting across studies. Our approach also demonstrates that current approaches based on unsupervised clustering lead to false discoveries related to novel cell-types.


  • Open Access

    Síndrome de piernas inquietas en esclerosis múltiple: evaluación de factores de riesgo y repercusión clínica

    by L. Lebrato Hernández, M. Prieto León, N.A. Cerdá Fuentes, A.J. Uclés Sánchez, J.L. Casado Chocán, M. Díaz Sánchez


  • Open Access

    Trombectomía con aspiración por captura (embaspiración) en el ictus isquémico agudo

    by A. de Albóniga-Chindurza, J. Ortega-Quintanilla, F. Moniche, L. San Román, E. Zapata-Arriaza, I. Escudero-Martínez, M. Zapata, S. Pérez-Sánchez, M.A. Gamero, A. Barragán-Prieto, et al.


  • Open Access

    Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

    by Paula Marazuela, Anna Bonaterra-Pastra, Júlia Faura, Anna Penalba, Jesús Pizarro, Olalla Pancorbo, David Rodríguez-Luna, Carla Vert, Alex Rovira, Francesc Pujadas, et al.

    Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.


  • Open Access

    Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

    by Anna Bonaterra-Pastra, Sofia Fernández-De-Retana, Andrea Rivas-Urbina, Núria Puig, Sònia Benítez, Olalla Pancorbo, David Rodríguez-Luna, Francesc Pujadas, Maria del Mar Freijo, Silvia Tur, et al.

    Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.


  • Open Access

    Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders

    by Pablo García-Miranda, Francisco J. Morón-Civanto, Maria del Mar Martínez-Olivo, Nela Suárez-Luna, Reposo Ramírez-Lorca, Lucía Lebrato-Hernández, Raquel Lamas-Pérez, Guillermo Navarro, Javier Abril-Jaramillo, Maria Isabel García-Sánchez, et al.

    The detection of IgG aquaporin-4 antibodies in the serum of patients with Neuromyelitis optica (NMO) has dramatically improved the diagnosis of this disease and its distinction from multiple sclerosis. Recently, a group of patients have been described who have an NMO spectrum disorder (NMOsd) and who are seronegative for AQP4 antibodies but positive for IgG aquaporin-1 (AQP1) or myelin oligodendrocyte glycoprotein (MOG) antibodies. The purpose of this study was to determine whether AQP1 and MOG could be considered new biomarkers of this disease; and if point mutations in the gDNA of AQP4, AQP1 and MOG genes could be associated with the etiology of NMOsd. We evaluated the diagnostic capability of ELISA and cell-based assays (CBA), and analyzed their reliability, specificity, and sensitivity in detecting antibodies against these three proteins. The results showed that both assays can recognize these antigen proteins under appropriate conditions, but only anti-AQP4 antibodies, and not AQP1 or MOG, appears to be a clear biomarker for NMOsd. CBA is the best method for detecting these antibodies; and serum levels of AQP4 antibodies do not correlate with the progression of this disease. So far, the sequencing analysis has not revealed a genetic basis for the etiology of NMOsd, but a more extensive analysis is required before definitive conclusions can be drawn.


  • Open Access

    Mediterranean Diet and Physical Activity Protect from Silent Brain Infarcts in a Cohort of Patients with Atrial Fibrillation

    by Irene Escudero-Martínez, Fernando Mancha, Ángela Vega-Salvatierra, María Irene Ayuso, Rafael F. Ocete, Pilar Algaba, Antonio López-Rueda, Pilar Piñero, Elena Fajardo, José Román Fernández-Engo, et al.


  • Recurrent pseudotumoral relapses in multiple sclerosis: a case report

    by Lucía Lebrato Hernández, María Díaz Sánchez, María Prieto León, Nuria Alicia Cerdá Fuertes, Antonio José Uclés Sánchez, José Luis Casado Chocán


  • Open Access

    Corrigendum to “Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials”

    by Francisco Moniche, Paulo Henrique Rosado-De-Castro, Irene Escudero, Elena Zapata, Francisco Javier de la Torre Laviana, Rosalia Mendez-Otero, Magdalena Carmona, Pilar Piñero, Alejandro Bustamante, Lucía Lebrato, et al.

    [This corrects the article DOI: 10.1155/2016/8657173.].


  • Open Access

    Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials

    by Francisco Moniche, Paulo Henrique Rosado-De-Castro, Irene Escudero, Elena Zapata, Francisco Javier De La Torre Laviana, Rosalia Mendez-Otero, Magdalena Carmona, Pilar Piñero, Alejandro Bustamante, Lucía Lebrato, et al.

    Background and Purpose. BM‐MNC transplantation improves recovery in experimental models of ischemic stroke. Clinical trials are ongoing to test efficacy in stroke patients. However, whether cell dose is related to outcomes is not known. Methods. We performed a pooling data analysis of two pilot clinical trials with autologous BM‐MNCs transplantation in ischemic stroke patients. Cell dose and route were analyzed to evaluate their relation to good outcome (m‐Rankin scale [mRS] score 0–2) at 6 months. Results. Twenty‐two patients were included. A median of 153 × 106 (±121 × 106) BM‐MNCs was injected. Intra‐arterial route was used in 77.3% of cases. A higher number of cells injected were associated with better outcomes at 180 days (390 × 106 [320–422] BM‐MNCs injected in those patients with mRS of 0–2 at 6 months versus 130 × 106 [89–210] in those patients with mRS 3–6, p = 0.015). In the intra‐arterially treated patients, a strong correlation between dose of cells and disability was found (r = −0.63, p = 0.006). A cut point of 310 × 106 injected cells predicted good outcome with 80% sensitivity and 88.2% specificity. Conclusions. Similar to preclinical studies, a higher dose of autologous BM‐MNC was related to better outcome in stroke patients, especially when more than 310 × 106 cells are injected. Further interventional studies are warranted to confirm these data.